Rick Kendall

Based in California, Dr Rick Kendall is vice president of research at Kite Pharma and is responsible for the company’s research pipeline and developing CAR-T technology. Dr Kendall was executive director of Oncology Research at Amgen, where he directed a group of 90+ scientists, and was responsible for the development of the Amgen cancer franchise strategy aligning research with other functions including Chemistry, Protein Sciences, Medical Translational Sciences, Development and Commercial. Results included 17 clinical candidate molecules made up of 9 small molecules and 8 protein therapeutics. Dr Kendall holds an associate adjunct professor position in the Department of Molecular, Cellular and Developmental Biology, at the University of California at Santa Barbara. Prior to joining the board of Phylogica in April 2017, Dr Kendall has consulted on the development of the company’s assets including the iMyc oncology program and Functional Penetrating Phylomer (FPP) intracellular drug delivery technology.
Bio last updated 26 May 2018

Article Timeline

Positions - Previous

PositionCompanyYearCompany's current rank
Non-Executive DirectorPhylogica2017 - 2017113

Total Shareholder Return as at 30/04/18

1 year TSR5 year TSR
145thFamily Zone Cyber Safety79%0%
408thKatana Capital6%4%
469thMejority Capital-1%-10%
721 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

$28k Issued
$28k Issued
$47k Issued
Total value as at the date of the transaction
Source: Morningstar


121st↓Katana Capital$2.4m
123rd↓Mejority Capital$2.3m
124th↑Family Zone Cyber Safety$2.3m
238 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer